MAX

MAX BioPharma is a privately held, preclinical-stage biopharmaceutical company headquartered in Santa Monica, California, focused on developing a new class of small molecule therapeutics based on oxysterol biology. Utilizing its proprietary Oxysterol Therapeutics® platform, the company creates semi-synthetic oxysterol analogues that modulate key cellular signaling pathways involved in fibrosis, oncology, and bone regeneration. The lead candidate, Oxy210, is an orally bioavailable molecule designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and atherosclerosis by inhibiting TGF-beta, Hedgehog, and Toll-like receptor signaling. Other programs include Oxy133 for bone repair and spinal fusion, as well as candidates for pancreatic cancer and infectious diseases like tuberculosis and HBV. MAX BioPharma's approach aims to provide safer, more effective alternatives to current treatments for chronic inflammatory and age-related disorders.